Wenfeng Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wenfeng Zhang has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
Qi Zhang
Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China
3 shared publicationsDaxian Wu
Department of Infectious Diseases, the First Affiliated Hospital, Nanchang University, Nanchang, China
2 shared publications- Daxian Wu
Department of Infectious Diseases, The First Affiliated Hospital Nanchang University Nanchang China
2 shared publications Jiansheng Huang
Department of Infectious Diseases, the First Affiliated Hospital, Nanchang University, Nanchang, China
2 shared publicationsQunfang Rao
Department of Infectious Diseases, the First Affiliated Hospital, Nanchang University, Nanchang, China
2 shared publicationsXiaoping Wu
Department of Infectious Diseases, the First Affiliated Hospital, Nanchang University, Nanchang, China
2 shared publications
Latest Publications
- Open Access
- 1 July 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-12
Lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients
Background: COVID-19 continuously threated public health heavily. Present study aimed to investigate the lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients. Methods: Lymphocyte subsets was classified using flow cytometry with peripheral blood collected from 106 patients. Results: Multivariate logistic regression showed that chest tightness, lymphocyte count, and γ-glutamyl transpeptidase were the independent predictors for severe COVID-19. The T cell, CD4+ T cell and B cell counts in severe patients were significantly lower than that in mild patients (p = 0.004, 0.003 and 0.046, respectively). Only the T cell count was gradually decreased with the increase of infiltrated quadrants of lesions in computed tomography (CT) (p = 0.043). The T cell, CD4+ T cell, and CD8+ T cell counts were gradually decreased with the increase of infiltrated area of the maximum lesion in CT (p = 0.002, 0.003, 0.028; respectively). For severe patients, the counts of T cell, CD4+ T cell, CD8+ T cell gradually decreased with the increased delayed hospitalization (p = 0.001, 0.03, and < 0.001, respectively). The proportions of T cell, CD8+ T cell gradually decreased with the increased delayed hospitalization (both p < 0.001), but the proportions of NK cell, B cell gradually increased with the increased delayed hospitalization (p = 0.007, and 0.002, respectively). For mild patients, only the NK cell count was gradually decreased with the increased delayed hospitalization (p = 0.012). Conclusion: T lymphocyte and its subset negatively correlated with disease severity, CT manifestation and delayed hospitalization. The counts of lymphocyte subset were changed more profound than their proportions.
- 1 July 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-12
Open AccessLymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients
Background: COVID-19 continuously threated public health heavily. Present study aimed to investigate the lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients. Methods: Lymphocyte subsets was classified using flow cytometry with peripheral blood collected from 106 patients. Results: Multivariate logistic regression showed that chest tightness, lymphocyte count, and γ-glutamyl transpeptidase were the independent predictors for severe COVID-19. The T cell, CD4+ T cell and B cell counts in severe patients were significantly lower than that in mild patients (p = 0.004, 0.003 and 0.046, respectively). Only the T cell count was gradually decreased with the increase of infiltrated quadrants of lesions in computed tomography (CT) (p = 0.043). The T cell, CD4+ T cell, and CD8+ T cell counts were gradually decreased with the increase of infiltrated area of the maximum lesion in CT (p = 0.002, 0.003, 0.028; respectively). For severe patients, the counts of T cell, CD4+ T cell, CD8+ T cell gradually decreased with the increased delayed hospitalization (p = 0.001, 0.03, and < 0.001, respectively). The proportions of T cell, CD8+ T cell gradually decreased with the increased delayed hospitalization (both p < 0.001), but the proportions of NK cell, B cell gradually increased with the increased delayed hospitalization (p = 0.007, and 0.002, respectively). For mild patients, only the NK cell count was gradually decreased with the increased delayed hospitalization (p = 0.012). Conclusion: T lymphocyte and its subset negatively correlated with disease severity, CT manifestation and delayed hospitalization. The counts of lymphocyte subset were changed more profound than their proportions.
- Open Access
- 15 May 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5527-5537
The natural course of COVID‐19 patients without clinical intervention
The natural course of coronavirus disease 2019 (COVID‐19) patients without clinical intervention has not yet been documented. One hundred and fifty‐eight patients from two hospitals were enrolled to identify the indicators of severe COVID‐19 and observe the natural course of COVID‐19 patients without clinical intervention. The total computed tomography (CT) score, a quantitative score based on assessment of the number, quadrant, and area of the lesions in CT, tended to perform better than assessment based only on the number or area of the lesions (p = 0.0004 and p = 0.0887, respectively). Multivariate logistic regression showed that the total CT score, chest tightness, lymphocyte, and lactate dehydrogenase (LDH) were independent factors for severe COVID‐19. For patients admitted in 2 weeks from onset to hospitalization, the frequency of severe COVID‐19 was gradually increased with the delayed hospitalization. The symptoms of fatigue, dry cough, sputum production, chest tightness, and polypnea were gradually more frequent. The levels of C‐reactive protein, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, γ‐glutamyl transpeptidase, LDH, and d‐dimer were also gradually increased, as well as the scores based on CT. Conversely, the lymphocyte count and the albumin level were gradually decreased with the delayed hospitalization. Detail turning points of the above alterations were observed after 10–14 days from onset to hospitalization. Total CT score was a simple and feasible score for identifying severe COVID‐19. COVID‐19 patients without clinical intervention deteriorated gradually during the initial 10–14 days but gradually improved thereafter.
- 15 May 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5527-5537
Open AccessThe natural course of COVID‐19 patients without clinical intervention
The natural course of coronavirus disease 2019 (COVID‐19) patients without clinical intervention has not yet been documented. One hundred and fifty‐eight patients from two hospitals were enrolled to identify the indicators of severe COVID‐19 and observe the natural course of COVID‐19 patients without clinical intervention. The total computed tomography (CT) score, a quantitative score based on assessment of the number, quadrant, and area of the lesions in CT, tended to perform better than assessment based only on the number or area of the lesions (p = 0.0004 and p = 0.0887, respectively). Multivariate logistic regression showed that the total CT score, chest tightness, lymphocyte, and lactate dehydrogenase (LDH) were independent factors for severe COVID‐19. For patients admitted in 2 weeks from onset to hospitalization, the frequency of severe COVID‐19 was gradually increased with the delayed hospitalization. The symptoms of fatigue, dry cough, sputum production, chest tightness, and polypnea were gradually more frequent. The levels of C‐reactive protein, alanine aminotransferase, aspartate aminotransferase, total bilirubin, direct bilirubin, γ‐glutamyl transpeptidase, LDH, and d‐dimer were also gradually increased, as well as the scores based on CT. Conversely, the lymphocyte count and the albumin level were gradually decreased with the delayed hospitalization. Detail turning points of the above alterations were observed after 10–14 days from onset to hospitalization. Total CT score was a simple and feasible score for identifying severe COVID‐19. COVID‐19 patients without clinical intervention deteriorated gradually during the initial 10–14 days but gradually improved thereafter.
- Open Access
- 4 January 2021
- Published by Springer Nature in Research Square
Lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients
Background: COVID-19 continuously threated public health heavily. Present study aimed to investigate the lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients.Methods: Lymphocyte subsets was classified using flow cytometry with peripheral blood collected from 106 patients.Results: Multivariate logistic regression showed that chest tightness, lymphocyte count, and γ-glutamyl transpeptidase were the independent predictors for severe COVID-19. The T cell, CD4+ T cell and B cell counts in severe patients were significantly lower than that in mild patients (p = 0.004, 0.003 and 0.046, respectively). Only the T cell count was gradually decreased with the increase of infiltrated quadrants of lesions in computed tomography (CT) (p = 0.043). The T cell, CD4+ T cell, and CD8+ T cell counts were gradually decreased with the increase of infiltrated area of the maximum lesion in CT (p = 0.002, 0.003, 0.028; respectively). The T cell count, as well as CD4+ T cell, CD8+ T cell, and NK cell counts were gradually decreased with the increased delayed hospitalization (p = 0.003, 0.002, 0.013, and 0.012; respectively). The proportion of T cell was gradually decreased but B cell was gradually increased with the increased delayed hospitalization (p = 0.031 and 0.003, respectively).Conclusion: T cell and CD4+ T cell counts negatively correlated with disease severity, CT manifestation and delayed hospitalization. CD4+ T cell was mainstay of immunity response in COVID-19 patients.
- 4 January 2021
- Published by Springer Nature in Research Square
Open AccessLymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients
Background: COVID-19 continuously threated public health heavily. Present study aimed to investigate the lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients.Methods: Lymphocyte subsets was classified using flow cytometry with peripheral blood collected from 106 patients.Results: Multivariate logistic regression showed that chest tightness, lymphocyte count, and γ-glutamyl transpeptidase were the independent predictors for severe COVID-19. The T cell, CD4+ T cell and B cell counts in severe patients were significantly lower than that in mild patients (p = 0.004, 0.003 and 0.046, respectively). Only the T cell count was gradually decreased with the increase of infiltrated quadrants of lesions in computed tomography (CT) (p = 0.043). The T cell, CD4+ T cell, and CD8+ T cell counts were gradually decreased with the increase of infiltrated area of the maximum lesion in CT (p = 0.002, 0.003, 0.028; respectively). The T cell count, as well as CD4+ T cell, CD8+ T cell, and NK cell counts were gradually decreased with the increased delayed hospitalization (p = 0.003, 0.002, 0.013, and 0.012; respectively). The proportion of T cell was gradually decreased but B cell was gradually increased with the increased delayed hospitalization (p = 0.031 and 0.003, respectively).Conclusion: T cell and CD4+ T cell counts negatively correlated with disease severity, CT manifestation and delayed hospitalization. CD4+ T cell was mainstay of immunity response in COVID-19 patients.
- Open Access
Lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients
Background: COVID-19 continuously threated public health heavily. Present study aimed to investigate the lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients. Methods: Lymphocyte subsets was classified using flow cytometry with peripheral blood collected from 106 patients. Results: Multivariate logistic regression showed that chest tightness, lymphocyte count, and γ-glutamyl transpeptidase were the independent predictors for severe COVID-19. The T cell, CD4 + T cell and B cell counts in severe patients were significantly lower than that in mild patients (p = 0.004, 0.003 and 0.046, respectively). Only the T cell count was gradually decreased with the increase of infiltrated quadrants of lesions in computed tomography (CT) (p = 0.043). The T cell, CD4 + T cell, and CD8 + T cell counts were gradually decreased with the increase of infiltrated area of the maximum lesion in CT (p = 0.002, 0.003, 0.028; respectively). The T cell count, as well as CD4 + T cell, CD8 + T cell, and NK cell counts were gradually decreased with the increased delayed hospitalization (p = 0.003, 0.002, 0.013, and 0.012; respectively). The proportion of T cell was gradually decreased but B cell was gradually increased with the increased delayed hospitalization (p = 0.031 and 0.003, respectively). Conclusion: T cell and CD4 + T cell counts negatively correlated with disease severity, CT manifestation and delayed hospitalization. CD4 + T cell was mainstay of immunity response in COVID-19 patients.
Open AccessLymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients
Background: COVID-19 continuously threated public health heavily. Present study aimed to investigate the lymphocyte subset alterations with disease severity, imaging manifestation, and delayed hospitalization in COVID-19 patients. Methods: Lymphocyte subsets was classified using flow cytometry with peripheral blood collected from 106 patients. Results: Multivariate logistic regression showed that chest tightness, lymphocyte count, and γ-glutamyl transpeptidase were the independent predictors for severe COVID-19. The T cell, CD4 + T cell and B cell counts in severe patients were significantly lower than that in mild patients (p = 0.004, 0.003 and 0.046, respectively). Only the T cell count was gradually decreased with the increase of infiltrated quadrants of lesions in computed tomography (CT) (p = 0.043). The T cell, CD4 + T cell, and CD8 + T cell counts were gradually decreased with the increase of infiltrated area of the maximum lesion in CT (p = 0.002, 0.003, 0.028; respectively). The T cell count, as well as CD4 + T cell, CD8 + T cell, and NK cell counts were gradually decreased with the increased delayed hospitalization (p = 0.003, 0.002, 0.013, and 0.012; respectively). The proportion of T cell was gradually decreased but B cell was gradually increased with the increased delayed hospitalization (p = 0.031 and 0.003, respectively). Conclusion: T cell and CD4 + T cell counts negatively correlated with disease severity, CT manifestation and delayed hospitalization. CD4 + T cell was mainstay of immunity response in COVID-19 patients.
- Open Access
- 1 December 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (51) , e9431
Acute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer
Keytruda (pembrolizumab) is an inhibitor of programmed cell death receptor-1 (PD-1), which was approved to treat advanced melanoma and nonsmall cell lung cancer patients who do not respond to other treatment. However, its efficacy and security in the treatment of advanced liver cancer is still under investigation. A 60-year-old man was diagnosed with pulmonary metastatic liver cancer who accepted pembrolizumab treatment after the failure of sorafenib. When injected pembrolizumab, in spite of pulmonary metastatic lesion shrink, the patient experienced severe liver dysfunction. Based on the features of the clinical signs and laboratory examination, the patient was diagnosed with pembrolizumab-induced immune-related hepatitis by excluding other etiologies and drug-induced side effects. The patient received glucocorticoid and artificial liver (plasma exchange) therapy after failed conservative liver protection treatment. The patient's liver dysfunction continuously progressed and he finally died of liver failure and its complications during his hospitalization. Pembrolizumab showed efficacy in an advanced hepatocellular carcinoma patient with lung metastases. However, it can generate immune-related adverse events such as immune-related hepatitis which can be lethal.
- 1 December 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (51) , e9431
Open AccessAcute liver failure caused by pembrolizumab in a patient with pulmonary metastatic liver cancer
Keytruda (pembrolizumab) is an inhibitor of programmed cell death receptor-1 (PD-1), which was approved to treat advanced melanoma and nonsmall cell lung cancer patients who do not respond to other treatment. However, its efficacy and security in the treatment of advanced liver cancer is still under investigation. A 60-year-old man was diagnosed with pulmonary metastatic liver cancer who accepted pembrolizumab treatment after the failure of sorafenib. When injected pembrolizumab, in spite of pulmonary metastatic lesion shrink, the patient experienced severe liver dysfunction. Based on the features of the clinical signs and laboratory examination, the patient was diagnosed with pembrolizumab-induced immune-related hepatitis by excluding other etiologies and drug-induced side effects. The patient received glucocorticoid and artificial liver (plasma exchange) therapy after failed conservative liver protection treatment. The patient's liver dysfunction continuously progressed and he finally died of liver failure and its complications during his hospitalization. Pembrolizumab showed efficacy in an advanced hepatocellular carcinoma patient with lung metastases. However, it can generate immune-related adverse events such as immune-related hepatitis which can be lethal.